Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
14 févr. 2024 12h29 HE
|
Gain Therapeutics, Inc.
BETHESDA, Md., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of...
Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update
31 janv. 2024 08h00 HE
|
Gain Therapeutics, Inc.
BETHESDA, Md., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain,” or the “Company”), a biotechnology company leading the discovery and development of allosteric small...